NCT07275242 A Clinical Study of SHR-A1811(sc) Subcutaneous Injection in Patients With Solid Tumor
| NCT ID | NCT07275242 |
| Status | Recruiting |
| Phase | Phase 1 |
| Sponsor | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
| Condition | Solid Tumor |
| Study Type | INTERVENTIONAL |
| Enrollment | 107 participants |
| Start Date | 2025-12-23 |
| Primary Completion | 2027-06 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 1 is the earliest stage of human testing — safety and dosage are the primary focus. Visits are frequent and medical supervision is intensive. You will be among the first people to receive this treatment.
This trial targets 107 participants in total. It began in 2025-12-23 with a primary completion date of 2027-06.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is being conducted to evaluate the pharmacokinetics , safety, tolerability and efficacy in patients with solid tumor.
Eligibility Criteria
Inclusion Criteria: 1. ≥18 years of age; 2. Solid Tumor confirmed by histology or cytology; 3. ECOG score is 0 or 1; 4. An expected survival of ≥ 12 weeks; 5. At least one measurable lesion according to RECIST v1.1 criteria; 6. Have adequate renal and hepatic function; 7. Patients voluntarily joined the study and signed informed consent. Exclusion Criteria: 1. With a history of any malignancies in the past 5 years, excluding cured cervical carcinoma in situ and melanoma skin cancer; 2. Patients have major surgical procedures or radiotherapy / chemotherapy within 4 weeks before the first medication; 3. History of immunodeficiency; 4. Clinically significant cardiovascular diseases; 5. Known or suspected interstitial lung disease; 6. Known hereditary or acquired bleeding thrombotic tendency; 7. Active hepatitis and liver cirrhosis; 8. Known allergic history of the drug components of this protocol; 9. History of neurological or psychiatric disorders.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07275242 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Solid Tumor. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07275242 trial and what does that mean for participants?
Phase 1 trials are the first stage of human testing. The primary goal is to assess safety and determine appropriate dosage levels. Participants are closely monitored. These trials typically involve a small number of volunteers.
Is NCT07275242 currently recruiting?
Yes, NCT07275242 is actively recruiting participants. Contact the research team at yue.zhang@hengrui.com for enrollment information.
Where is the NCT07275242 trial being conducted?
This trial is being conducted at Guangzhou, China.
Who is sponsoring the NCT07275242 clinical trial?
NCT07275242 is sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd.. The trial plans to enroll 107 participants.